[ Price : $8.95]
FDA will give priority review to a Sprout sNDA to expand the indication for Addyi to treat low sexual desire in post-menopausal wo...[ Price : $8.95]
FDA reportedly is requiring additional safety data from Sarepta Therapeutics before the agency considers supporting use of the com...[ Price : $8.95]
HHS secretary Robert F. Kennedy, Jr. approves a new federal directive removing thimerosal, a mercury-based preservative, from all ...[ Price : $8.95]
FDA solicits statements of interest in being one of no more than five drug and biologic developers to participate in the initial c...[ Price : $8.95]
University researchers say they found relatively few instances in which Oncology Drugs Advisory Committee members reported difficu...[ Price : $8.95]
CDER issues a white paper tracing the history of selective safety data collection (SSDC) and plans for the future.[ Price : $8.95]
FDA extends by three months its review of a GSK BLA for Blenrep (belantamab mafodotin) combinations for treating patients with rel...[ Price : $8.95]
Apnimed announces positive topline results from its second pivotal Phase 3 trial of AD109 (aroxybutynin and atomoxetine), a once-d...